These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21078047)

  • 1. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
    Procopio G; Guadalupi V; Giganti MO; Mariani L; Salvioni R; Nicolai N; Capone F; Valdagni R; Bajetta E
    BJU Int; 2011 Jul; 108(2):223-7. PubMed ID: 21078047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer.
    Harris KA; Weinberg V; Bok RA; Kakefuda M; Small EJ
    J Urol; 2002 Aug; 168(2):542-5. PubMed ID: 12131305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary hormonal manipulations in the treatment of castration refractory prostate cancer.
    Agarwal N; Vogelzang NJ
    BJU Int; 2011 Jul; 108(2):227-8. PubMed ID: 21410863
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).
    Small EJ; Halabi S; Dawson NA; Stadler WM; Rini BI; Picus J; Gable P; Torti FM; Kaplan E; Vogelzang NJ
    J Clin Oncol; 2004 Mar; 22(6):1025-33. PubMed ID: 15020604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration.
    Lin GW; Yao XD; Ye DW
    BJU Int; 2011 Apr; 107(8):1326-7; author reply 1327. PubMed ID: 21929520
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective analysis of the consequences of acid suppressive therapy on ketoconazole efficacy in advanced castration-resistant prostate cancer.
    Keisner SV; Shah SR; Jean GW; Ussery SM; Dowell JE
    Ann Pharmacother; 2010 Oct; 44(10):1538-44. PubMed ID: 20841515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR; Zietman AL; Finkelstein JS; Wu CL
    N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract]   [Full Text] [Related]  

  • 8. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of low dose ketoconazole therapy for Chinese patients with castration resistant prostate cancer].
    Lin GW; Ye DW; Yao XD; Zhang SL; Dai B; Zhang HL; Shen YJ; Zhu Y; Zhu YP; Shi GH; Ma CG; Xiao WJ; Qin XJ
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):520-3. PubMed ID: 22490153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.
    Nakabayashi M; Xie W; Regan MM; Jackman DM; Kantoff PW; Oh WK
    Cancer; 2006 Sep; 107(5):975-81. PubMed ID: 16862573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A; Masumori N; Hashimoto J; Kyoda Y; Yanase M; Tsukamoto T
    Jpn J Clin Oncol; 2010 Dec; 40(12):1154-8. PubMed ID: 20647233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Castration of prostate cancer patients and cognition].
    Portin R; Koskinen A; Helenius H; Nurmi M; Salminen E
    Duodecim; 2005; 121(16):1784-5. PubMed ID: 16268226
    [No Abstract]   [Full Text] [Related]  

  • 14. Adrenal androgen levels as predictors of outcome in castration-resistant prostate cancer patients treated with combined androgen blockade using flutamide as a second-line anti-androgen.
    Narimoto K; Mizokami A; Izumi K; Mihara S; Sawada K; Sugata T; Shimamura M; Miyazaki K; Nishino A; Namiki M
    Int J Urol; 2010 Apr; 17(4):337-45. PubMed ID: 20202011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.
    Nakabayashi M; Oh WK; Jacobus S; Regan MM; Taplin ME; Kantoff PW; Rosenberg JE
    BJU Int; 2010 May; 105(10):1392-6. PubMed ID: 19863532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.
    Ryan CJ; Weinberg V; Rosenberg J; Fong L; Lin A; Kim J; Small EJ
    J Urol; 2007 Dec; 178(6):2372-6; discussion 2377. PubMed ID: 17936834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diferelin treatment of primary local and generalized cancer of the prostate].
    Kolesnikov GP; Rusakov IG; Shaplygin LV; Voznesenskiĭ SA; Bystrov AA
    Urologiia; 2001; (6):17-9. PubMed ID: 11785073
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.